CB 0006

Drug Profile

CB 0006

Latest Information Update: 27 Apr 2005

Price : $50

At a glance

  • Originator Celltech Group
  • Class Antibacterials; Antimalarials; Antiseptics; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Malaria; Sepsis

Most Recent Events

  • 27 Apr 2005 Celltech Group has since been acquired by UCB.
  • 28 Aug 1997 Discontinued-II for Malaria in Gambia (IV)
  • 26 Apr 1995 Discontinued-II for Sepsis in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top